Hybridomas are obtained by fusing normal B lymphocytes with a myeloma (tumor B cell line). Thus, a cloned hybridoma cell line has an unlimited capacity to grow in culture, producing immunoglobulin molecules with identical structure and antigen specificity, termed monoclonal antibodies (mAbs), which may have a wide variety of applications.

BACKGROUND

Monoclonal antibodies specific for molecules expressed by leukocytes, termed “leukocyte differentiation antigens” (CD) are used in biomedical research, as well as for the detection of biomarkers with diagnostic, prognostic and/or therapeutic interest in the clinical management of different diseases. Our clone UP-H2 was validated in the panel for the diagnosis of a subset of acute myeloid leukemias according to Euroflow, a consortium funded by the European Union to define suitable markers for hematopoietic malignancies.

CATALOGUE

LICENSE CONDITIONS

COMMERCIAL OPPORTUNITY

CONTACT

KEYWORDS